What are the characteristics of AELIS FARMA stock?

AELIS FARMA is a company operating in the Biotechnologies sector. The stock is listed on Euronext Paris under ISIN FR0014007ZB4.

What is the recent price evolution of AELIS FARMA stock?

Since last close: -0.28 %. Over one week: -6.75 %. Over one year: -36.18 %.

Aelis Farma: Green Light from Independent Committee to Continue Phase 2b of AEF0217

The biotech company from Bordeaux, Aelis Farma, has received a favorable opinion from the independent data monitoring committee to continue the phase 2b clinical trial of its candidate AEF0217, aimed at treating behavioral and cognitive disorders in individuals with Down syndrome.

Published on Jul 18, 2026 at 10:12

AELIS FARMA

0.72 € -0.28 %

Add us as a preferred source on Google

Green Light from Monitoring Committee to Continue Study

The independent data monitoring committee has recommended continuing the phase 2b trial with AEF0217 in patients with Down syndrome. This positive opinion validates the clinical trajectory of the program and allows the company to maintain its schedule for evaluating the candidate in this therapeutic indication.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ UCB share price breaks through €219 and surges nearly 12% following raised targets 🗞️ Nanobiotix share declines 1% but posts +22% on the week 🗞️ Abivax stock drops 30% over the quarter and turns red again 🗞️ Valneva stock breaks below its €2.42 support level and continues to decline

Context

Period

Period: S1 2026

Key reported figures

Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Net income: -2,4 millions d'euros
-2,2 millions d'euros

Guidance from the release

« Nous abordons le second semestre 2026 avec confiance » (mot du DG) ; « la trésorerie disponible […] lui permet de financer ses activités jusqu'au début de l'année 2028, sur la base des hypothèses suivantes : […] en obtenant des reports d'échéances de remboursement, en cours de négociation, pour 0,5 million d'euros »

Risks mentioned

Execution of the AEF0217 Phase 2b clinical study in three countries is subject to recruitment progressing on schedule and regulatory compliance
Financial visibility through early 2028 is dependent on cost control plan execution and successful securing of non-dilutive funding
Business development efforts for AEF0117 require identification of an appropriate industry partner to finance next development stages

Opportunities identified

Positive EMA Pediatric Committee opinion on AEF0217 Pediatric Investigation Plan secures development pathway in pediatric populations through young adults
€458,000 France 2030 grant award in April 2026 accelerates development of new CB1-SSi compounds for obesity and metabolic diseases without dilution
AEF0217 Phase 2b international study (France, Spain, Italy) advancing on schedule with 188 participants and expected results before end of Q4 2027

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Green Light from Monitoring Committee to Continue Study

Context

Also read